N/A N=36 Spinal Cord Injury Program in Exercise
Spinal Cord Injuries
Primary: Physical Activity Level at Week 8 — 383; 297 Minutes per week
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 PH94B in the Treatment of Adjustment Disorder With Anxiety
Adjustment Disorder With Anxious Mood
Primary: Hamilton Anxiety Scale (HAM-A) Score — -12.5; -12.6 score on a scale — p=0.9338
Phase 3 N=12,979 Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Onchocerciasis
Primary: Incidence and Severity of Treatment Emergent Adverse Events — 346; 79; 1199; 288 participants
Phase 3 N=100 Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
HIV Infections
Primary: Number of Participants With Continued Access to Age Appropriate Formulation of Dolutegravir — 53; 29 Participants
N/A N=50 Safety, Tolerability, and Biosignature of Humanized Prebiotics in Healthy Adults
Intestinal Health
Primary: Mean Composite PROMIS Maximum Scores — 4.3; 5.0; 3.0; 4.4 score on a scale
Phase 1 N=29 Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201
Myopia
Primary: Number of Unexpected Adverse Events — 41 adverse events
Phase 1 N=12 Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers
Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects · Apathy
Primary: Determination of Maximum Plasma Concentration [Cmax] of IRL757 — 2.88; 11.42 μmol/L
Phase 2 N=50 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
N/A N=44,729 SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Testing Among Utah Community Health Centers
Covid19
Primary: Reach-TM Engage — 2594; 2401 Participants
N/A N=33 Assessing Electronic Cigarette Nicotine Flux
Electronic Cigarette Use
Primary: Plasma Nicotine Concentration — 2.00; 1.92; 1.64; 1.62 mg/ml
N/A N=31 LIFUP for Treatment of Motor Deficits in Parkinson's Disease
Parkinson Disease
Primary: Motor Assessment 1: Unified Parkinson Disease Rating Scale (UPDRS) Section 3 — 37.24; 35.14; 36.93; 34.21 score on a scale
N/A N=10 Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis
Chronic Pancreatitis
Primary: Proportion of Approached Individuals Who Met Eligibility Criteria — 12 Participants
Phase 3 N=14 Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs) — 5; 58; 54; 63 Participants
N/A N=10 Oral Cladribine B-cell Study
Multiple Sclerosis
Primary: Percent Change in Class-switched Memory B Cells From Baseline to Week 96 nh — -62.8 % change
N/A N=10 Benefits of Bimodal Streaming With MED-EL Cochlear Implants and Starkey Hearing Aids
Hearing Loss, Sensorineural · Sensorineural Hearing Loss, Bilateral · Cochlear Implant Recipients
Primary: User Satisfaction With DualSync Bimodal Streaming Over Existing Bluetooth Streaming Option. — 2; 6; 7; 6 Participants